Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: Comparison with the National Cancer Institute data

Anti-Cancer Drugs

Volumn 18, Issue 4, 2007, Pages 389-404

  Bracht, Karin ^a   Liebeke, Manuel ^a   Ritter, Christoph A ^a   Grünert, Renate ^a   Bednarski, Patrick J ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Antioxidative enzymes; ATP binding cassette transporters; Correlation analysis; Cytotoxic drugs; Glutathione; Resistance

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; AZATHIOPRINE; CAMPTOTHECIN; CARBOPLATIN; CHLORAMBUCIL; COLCHICINE; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; HYDROXYUREA; IRINOTECAN; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; THIOREDOXIN REDUCTASE; THIOTEPA; VINBLASTINE; ABC TRANSPORTER; ANTIOXIDANT; CARRIER PROTEIN; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CORRELATION ANALYSIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STANDARDIZATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECT; FACTUAL DATABASE; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DATABASES, FACTUAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HUMANS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; THIOREDOXIN REDUCTASE (NADPH);

EID: 34247604600     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280140001     Document Type: Article

References (64)

1. Mansson E, Paul A, Löfgren C, Ullberg C, Paul C, Eriksson S, Albertioni F. Cross-resistance to cytosine arabinoside in a multidrug-resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy. Br J Haematol 2001; 114:557-565.
2. Jönsson K, Dahlberg N, Tidefelt U, Paul C, Andersson G. Characterization on an anthracycline-resistant human promyelocytic leukemia (HL-60) cell line with an elevated MDR-1 gene expression. Biochem Pharmacol 1995; 49:755-762.
3. Polgar O, Bates SE. ABC transporters in the balance: is there a role in multidrug resistance? Biochem Soc Transact 2005; 33:241-245.
4. Kerb R, Hoffmeyer S, Brinkmann S. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1, MRP2. Pharmacogenetics 2001; 2:51-64.
5. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58:931-959.
6. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5:219-234.
7. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
8. Ohlenschläger G. Das glutathionsystem. Berlin: Verlag für Medizin; 1991.
9. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54:4313-4320.
10. Smith IK, Vierheller TL, Thorne CA. Assay of glutathione reductase in crude tissue homogenates using 5,5′-dithiobis (2-nitrobenzoic acid). Anal Biochem 1988; 175:408-413.
11. López-Barea J, Bárcena JA, Bocanegra JA, Florindo J, García-Alfonso C, López-Ruiz A, et al. Structure, mechanism, functions, and regulatory properties of glutathione reductase. In: Vina J, editor. Glutathione: metabolism and physiological functions. New York: CRC Press; 1990. pp. 105-116.
12. Mustacich D, Powis G. Thioredoxin reductase. Biochem J 2000; 346:1-8.
13. Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system. Cancer Biol Ther 2005; 4:6-13.
14. Mannervik B. Glutatione peroxidase. Methods Enzymol 1985; 252: 490-495.
15. Ahmad S. Antioxidant mechanisms of enzymes and proteins. In: Ahmad S, editor. Oxidative stress and antioxidant defences in biology. New York: Chapman & Hall; 1995. pp. 238-265.
16. Cadenas E. Mechanism of oxygen activation and reactive oxygen species detoxification. In: Ahmad S, editor. Oxidative stress and antioxidant defences in biology. New York: Chapman & Hall; 1995.
17. Ursini F, Maiorino M, Brigelius-Flohé R, Aumann KD, Roveri A, Schomburg D, Flohé L. Diversity of glutathione peroxidase. Methods Enzymol 1985; 252:38-53.
18. Sandström BE, Marklund SL. Effects of variation in glutathione peroxidase activity on DNA damage and cell survival in human cells exposed to hydrogen peroxide and t-butyl hydroperoxide. Biochem J 1990; 271:17-23.
19. Waxman DJ. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy-a review. Cancer Res 1990; 50:6449-6454.
20. O'Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Eur J Cancer 1996; 32A:967-978.
21. Bio CD, Federici G. Glutathione transferase in human tumors and human cancer cell lines. In: Vina J, editor. Glutathione: metabolism and physiological functions. New York: CRC Press; 1990. pp. 117-123.
22. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989; 81:1088-1092.
23. Bracht K, Boubakari , Grünert R, Bednarski PJ. Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data. Anticancer Drugs 2006; 17:41-51.
24. Kum-Tatt L, Tan I, Seet A. A new colorimetric method for the determination of NADH/NADPH dependent glutathione reductase in erythrocytes and in plasma. Clin Chim Acta 1975; 58:101-108.
25. Smith IK, Vierheller TL, Thorne CA. Assay of glutathione reductase in crude tissue homogenates using 5,5′-dithiobis (2-nitrobenzoic acid). Anal Biochem 1988; 175:408-413.
26. Cribb AE, Leeder JS, Spielberg SP. Use of a microplate reader in an assay of glutathione reductase using 5,5′-dithiobis(2-nitrobenzoic acid). Anal Biochem 1989; 183:195-196.
27. Neumann C, Boubakari , Gruenert R, Bednarski PJ. Nicotinamide adenine dinucleotide phosphate-regenerating system coupled to a glutathione-reductase microtiter method for determination of total glutathione concentrations in adherent growing cancer cell lines. Anal Biochem 2003; 320:170-178.
28. Holmgren A, Björnstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol 1995; 252:199-208.
29. Gromer S, Merkle H, Schirmer RH, Becker K. Human placenta thioredoxin reductase: preparation and inhibitor studies. Methods Enzymol 2002; 347:382-394.
30. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferase. J Biol Chem 1974; 249:7130-7139.
31. Paglia DE, Valentine DE. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70:158-169.
32. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
33. Towbin H, Staehlein T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979; 76:4350-4354.
34. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol Int 1998; 111-112:1-14.
35. Austin L, Arthur H, De Niese M, Gurusinghe A, Baker MS. Micromethods in single muscle fibers: 2. Determination of glutathione reductase and glutathione peroxidase. Anal Biochem 1988; 174:575-579.
36. Kodera Y, Isobe K, Yamauchi M, Kondo K, Akiyama S, Ito K, et al. Expression of glutathione-S-transferases α and π in gastric cancer: a corrleation with cisplatin resistance. Cancer Chemother Pharmacol 1994; 34:203-208.
37. Tew KD, Monks A, Barone L, Rosser D, Akerman D, Montali J, et al. Glutathione-associated enzymes in the human cell lines of the national cancer institute drug screening program. Mol Pharmacol 1996; 50:149-159.
38. Sharma R, Singhal SS, Srivastava SK, Bajpai KK, Frenkel EP, Awasthi S. Glutathione and glutathione linked enzymes in human small cell lung cancer. Cancer Lett 1993; 75:111-119.
39. Castro VM, Söderström M, Carlberg I, Widersten M, Platz A, Mannervik B. Differences among human tumor cell lines in the expression of glutathione transferases and other glutathione-linked enzymes. Carcinogenesis 1990; 11:1569-1576.
40. Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T. Cisplatin resistance and transcription factors. Curr Med Chem 2005; 5:15-27.
41. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level [review]. Oncol Rep 2003; 10:1663-1682.
42. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 2004; 64:356-362.
43. Welters MJP, Fichtinger-Shepman AMJ, Baan RA, Flens MJ, Sheper RJ, Braakhuis BJM. Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines. Br J Cancer 1998; 77:556-561.
44. Komiya S, Gebhardt MC, Mangham DC, Inoue A. Role of glutathione in cisplatin resistance in osteosarcoma cell lines. J Orth Res 1998; 16:15-22.
45. Dirven HAAM, Dictus ELJT, Broeders NLHL, van Ommen B, van Bladeren PJ. The role of human glutathione S-transferase isoenzymes in the formation of glutathione konjugates of the alkylating cytostatic drug thiotepa. Cancer Res 1995; 55:1701-1706.
46. Wang Y, Teicher BA, Shea TC, Holden SA, Rosbe KW, Al-Achi A, et al. Cross-resistance and glutathione-S-tansferase-p levels among four human melanoma cell lines selected for alkylating agent resistance. Cancer Res 1989; 49:6185-6192.
47. Ritter CA, Sperker B, Grube M, Dressel D, Kunert-Keil C, Kroemer HK. Overexpression of glutathione-S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression. Br J Pharmacol 2002; 137:1100-1106.
48. Saito Y, Yoshida Y, Akazawa T, Takahashi K, Niki E. Cell death caused by selenium deficiency and protective effect of antioxidants. J Biol Chem 2003; 278:39426-39434.
49. Akman SA, Forrest G, Chu F, Esworthy RS, Doroshow JH. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. Cancer Res 1990; 50:1397-1402.
50. Milano G, Caldani C, Khater R, Launay JM, Soummer AM, Namer M, et al. Time and dose-dependent inhibitions of erythrocyte glutathione peroxidase by cisplatin. Biochem Pharmacol 1988; 37:981-982.
51. Zhong L, Holmgren A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J Biol Chem 2000; 275:18121-18128.
52. Arnér ESJ, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000; 267:6102-6109.
53. Becker K, Gromer S, Schirmer RH, Müller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 2000; 267:6118-6125.
54. Fujiwara N, Fujii T, Fujii J, Taniguchi N. Functional expression of rat thioredoxin reductase: selenocysteine insertion sequence element is essential for the active enzyme. Biochem J 1999; 340:439-444.
55. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, et al. Cellular Levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 1995; 55:4293-4296.
56. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1, MRP2. Pharmacogenetics 2001; 2:51-64.
57. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91:4480-4488.
58. Szakács G, Paterson JK, Ludwig JA, Boothe-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5:219-234.
59. Polgar O, Bates SE. ABC transporters in the balance: is there a role in multidrug resistance? Biochem Soc Transact 2005; 33:241-245.
60. Alvarez M, Robey R, Sandor V, Nishiyama K, Matsumoto Y, Paull K, et al. Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles. Mol Pharmacol 1998; 54:802-814.
61. Cnubben NHP, Rommens AJM, Oudshoorn MJ, van Bladeren PJ. Glutathione-dependent biotransformation of the alkylating drug thiotepa and transport of its metabolite monoglutathionylthiotepa in human MCF-7 breast cancer cells. Cancer Res 1998; 58:4616-4623.
62. Xu H, Choi SM, An CS, Min YD, Kim KC, Kim KJ. Concentration dependant sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochem Biophys Res Commun 2005; 328:618-622.
63. Paumi CM, Ledford BG, Smitherman PK, Townsend AJ, Morrow CS. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase in alkylating agent resistance. J Biol Chem 2001; 276:7952-7956.
64. Nishioka C, Sakaeda T, Nakamura T, Moriya Y, Okamura N, Tamura T. MDR1, MRP1 and MRP2 genotypes and in vitro chemosensitivity in Japanese patients with colorectal adenocarcinomas. Kobe J Med Sci 2004; 50: 181-188.